A practical guide to understanding, using and including patient reported outcomes in clinical trials in ovarian cancer

about

A practical guide to understanding, using and including patient reported outcomes in clinical trials in ovarian cancer

Item

http://www.wikidata.org/entity/Q57164771

description

scientific article published on 09 June 2018

@en

wetenschappelijk artikel

@nl

наукова стаття, опублікована у вересні 2018

@uk

name

A practical guide to understan ...... nical trials in ovarian cancer

@en

A practical guide to understan ...... nical trials in ovarian cancer

@nl

type

Item

label

A practical guide to understan ...... nical trials in ovarian cancer

@en

A practical guide to understan ...... nical trials in ovarian cancer

@nl

prefLabel

A practical guide to understan ...... nical trials in ovarian cancer

@en

A practical guide to understan ...... nical trials in ovarian cancer

@nl

P1476

A practical guide to understan ...... nical trials in ovarian cancer

@en

P2093

Michael Friedlander

http://www.w3.org/2001/XMLSchema#string

Michelle K Wilson

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution-NonCommercial 4.0 License

P2860

CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

Patient-reported outcomes: assessment and current perspectives of the guidelines of the Food and Drug Administration and the reflection paper of the European Medicines Agency

Design, implementation and reporting strategies to reduce the instance and impact of missing patient-reported outcome (PRO) data: a systematic review.

Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial.

Choosing between the EORTC QLQ-C30 and FACT-G for measuring health-related quality of life in cancer clinical research: issues, evidence and recommendations.

Recommendations on health-related quality of life research to support labeling and promotional claims in the United States.

Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE).

Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.

P304

e81

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.3802/JGO.2018.29.E81

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Rebecca Mercieca-Bebber

Michelle K Wilson

Michael Friedlander

P577

2018-06-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

2018-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30022641

http://www.w3.org/2001/XMLSchema#string

P921

quality of life

ovarian neoplasm

ovarian cancer

biomedical investigative technique

P932

6078895

http://www.w3.org/2001/XMLSchema#string